30 closest matches · ranked by relevance
Type 3 Von Willebrand's Disease
Primary: Centralized Factor VIII (FVIII) Procoagulant Activity (FVIII:C) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis — 2.42 IU/dL
Gingival Bleeding · Von Willebrand Diseases
Primary: Bleeding on Probing (BOP) — 14.5; 12.3 percentage of sites
Von Willebrand Diseases · Postpartum Hemorrhage
Primary: Volume of Quantitative Blood Loss at Delivery — 727.0; 539.7 mL
Von Willebrand Disease
Primary: Overall Hemostatic Efficacy as Assessed by the Investigator (Hemophilia Physician) — 11; 4; 7; 0 Participants
Von Willebrand Disease (VWD)
Primary: Spontaneous Annualized Bleeding Rate (sABR) — 1.430; 1.040; 0.000; 3.022 spontaneous bleeds per year
Von Willebrand Disease
Primary: Percentage of Participants With Treatment Success for Treated Bleeding Episodes — 100.0 Percent of participants
Von Willebrand Diseases
Primary: Total Annualized Bleeding Rate (TABR) — 29.13 Bleeding events per year
Von Willebrand Disease
Primary: Ratio of Annualized Bleeding Rate (ABR) for Spontaneous Bleeding Episodes (BEs) (On-study ABR / Historical ABR) Assessed by Investigator During Prophylactic Treatment…
Von Willebrand Diseases
Primary: Total Annualized Bleeding Rate (TABR) — 3.73; 4.28; 6.31; 5.24 bleeding events per year
Von Willebrand Disease
Primary: Total Annualised Bleeding Rate (TABR) During Prophylactic Treatment With Wilate. — 4.6; 3.7 Annualized number of bleeding episodes
Hemophilia A
Primary: To Assess the Immunogenicity of Plasma Derived VWF/FVIII and rFVIII Concentrates by Determining the Frequency of Inhibitor Development in the First 50 EDs or in the…
Gaucher Disease, Type 3
Primary: Change From Baseline to 12 Months (Week 53) in Hemoglobin Concentration — 2.15 g/dL
Prevent Bleeding in Major Surgery
Primary: Overall Hemostatic Efficacy (Success or Failure) of Wilate, Based on the Intra-operative Assessment of the Surgeon and the Post-operative Assessment by the Investigator…
Hemophilia A · Von Willebrand Disease
Primary: Biologic Effects by Coagulation Tests — 34.75; 143.4 percentage of normal
Von Willebrand Disease
Primary: >50% Reduction in PBAC (Pictorial Blood Assessment Chart) at 6 Months — 71 percentage of participants
Gaucher Disease, Type 3
Primary: Percent Change From Baseline in Spleen Volume Measured by MRI — -51.33 Percent change
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Time to Platelet Count Response — 2.69; 2.88 days — p== 0.0099
Von Willebrand Disease
Primary: Incidence of Adverse Drug Reactions (ADRs) (%) — 8; 1; 1; 3 Participants
Factor XIII Deficiency
Primary: Adverse Events — 42; 2; 2 participants
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Time-to-response of Treatment Defined by a Confirmed Recovery of Platelets ≥ 150,000/µL — 2.4; 4.3; 3; 4.9 days — p== 0.005
Idiopathic Thrombocytopenic Purpura
Primary: Response Rate — 81.3 percentage of responders
Hemophilia · Factor XIII Deficiency
Primary: Response to Treatment of Bleeding Events Requiring Additional Factor XIII Infusions — 30; 1; 0; 3 Number of bleeds
Factor XIII Deficiency
Primary: The Incidence of Spontaneous Bleeding Events Requiring Treatment (Treatment is Defined as Administration of a FXIII-Containing Product to Treat the Bleeding Event) — 0…
Severe Hemophilia A
Primary: Total Annualized Bleeding Rate (TABR) — 2.10 No. of BEs / year (ABR) — p=<0.0001
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
Factor XIII Deficiency
Primary: Peak FXIII Concentration at Steady State — 0.9 Units/mL
Hemophilia A With Inhibitors · Hemophilia B With Inhibitors
Primary: Proportion of Successfully Treated Mild/Moderate Bleeding Episodes — .849; .932 Proportion of Success of BEs
Diabetes Mellitus · Coronary Artery Disease
Primary: Inhibition of Platelet Aggregation (IPA) 4 Hours After Loading Dose Assessed by Accumetrics VerifyNow™ P2Y12 Assay — 9.4; 9.3; 89.3; 27.7 percent inhibition — p=<0.0001
Hepatitis C
Primary: Percentage of Treatment-Naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) Target Detected (TD) or Target Not Detected (TND) — 90.1…
Factor VIII Deficiency
Primary: Estimated Annualized Bleeding Rate (ABR) in Arm A: Prophylaxis — 0.71 episodes per participant per year